anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The incidence of spinal anesthesia-induced hypotension in pregnant women undergoing a cesarean section is high. A preoperative fluid bolus of undetermined volume is frequently administered to lower the incidence of maternal hypotension, with a somewhat poor efficacy. Recently, several investigations have shown that the use of a phenylephrine infusion after the induction of spinal anesthesia results in a significant reduction in hypotensive episodes. Given the high efficacy of this therapy (incidence of hypotension around 20%), it is possible to determine the effective volume of fluid which would prevent hypotension in 50% of the patients studied (ED50).

Healthy term pregnant women undergoing elective cesarean section under spinal anesthesia will be recruited in this trial. The spinal anesthesia regimen will be standardized and all subjects will receive a phenylephrine infusion. The fluid investigated is hydroxyethylstarch (HES) 130/0.4 (Volulyte(R)). The ED50 will be determined using an up-down sequential allocation method initially described by Dixon \& Massey. The determination of the HES ED50 will help the anesthesiologist in further treating maternal hypotension appropriately.
This study looks to compare pelvic misalignments of 30 subjects visualized before x-ray set up to the actual misalignments derived from x-ray mensuration. 30 outpatients at the Sherman College of Chiropractic Health Center were randomly chosen to participate, and were having x-rays taken as part of their normal course of care in order prevent unnecessary radiation exposure. Patients were told to march in place as they were positioned to the x-ray bucky. Once the patient was set to the bucky, the bucky was moved out of the way and the patient was visualized by a health center intern. The intern evaluated gluteal widths, gluteal fold heights, and foot flare. The bucky was then replaced without patient movement and x-rays were then taken. Two doctors with experience in Gonstead line analysis for the pelvis who were blinded to the x-ray findings, measured pelvic misalignments and the results were compared to the visual analysis.
The Diaphanous-related formins (DRFs) constitute a subclass of FH proteins known for their ability to bind activated Rho subfamily of small GTP-binding proteins which link FH proteins to cellular signalling pathways. The present inventor has identified a new homology domain unique to the DRFs that termed the DRF-autoregulatory domain (DAD) in the extreme Cterminus. DAD is involved in intramolecular binding with the GTPase binding domain (GBD) of the DRFs.  Disclosed herein are compositions and methods that can disrupt this binding, and cause changes in cells including actin polymerization and/or stabilization of actin fibers resulting in growth inhibition or cell death by apoptosis. A  preferred composition is peptide or polypeptide of no more than about 130 amino acids comprising the DAD peptide having the amino acid sequence [GA]-[VA]-M-D-x-L-L-E-x-L-[KRQ]-x-[GA]-[SGA]-[AP] (wherein amino acids within a set of brackets are interchangeable and x means any amino acid). Fusion proteins comprising DAD are also disclosed as are nucleic acids and expression vectors encoding these peptides and proteins.
Children will receive Fi02 80% until Et 02 70% before intubation, anaesthesia will be maintained with Fi02 35%. Then, shortly before the planned extubation, Fi02 will be increased again to 80%.
In patients who may be susceptible to the intracranial effects of CO2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), preservative-free morphine sulfate injection may reduce respiratory drive, and the resultant CO2 retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with preservative-free morphine sulfate injection. Preservative-free morphine sulfate injection should be used with extreme caution in patients with head injury or increased intracranial pressure. Pupillary changes (miosis) from morphine may obscure the existence, extent and course of intracranial pathology. High doses of neuraxial morphine may produce myoclonic events [see Warnings and Precautions (5.6)]. Clinicians should maintain a high index of suspicion for adverse drug reactions when evaluating altered mental status or movement abnormalities in patients receiving this modality of treatment.

Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of preservative-free morphine sulfate injection in patients with impaired consciousness or coma.
Sturge- Weber syndrome (SWS), is a rare neuro-cutaneous angiomatosis which affects male and females alike. The clinical manifestations include angiomas, haemangiomas of the lips, tongue and palatine region. The oral manifestations are usually unilateral and are susceptible to bleed. Patients can also present with macroglossia and maxillary bone hypertrophy which can lead to malocclusion of the oral cavity. Food accumulation due to occlusion can cause growth of bacteria which can intensify infections and can cause gingival hyperplasia. A case of a middle-aged 39 year old female was reported in the Ziauddin Hospital, Karachi on 2nd of February,2022 with the presenting complaints of intermittent fever and drowsiness for 10 days. On examination she had massive tongue enlargement, drooling, malocclusion, difficulty in eating and breathing. She was a known case of Sturgeweber syndrome. Based on the clinical and radiological findings, she was managed along the lines of prelaryngeal soft tissue and submandibular infection.
Patients with unresectable and metastatic SCCHN cancer who will receive anti-PD-1 treatment under SOC. SOC treatments currently include nivolumab and pembrolizumab ("anti-PD-1 treatment"). The protocol may be amended to include other agents should they become SOC. Patients will receive a baseline \[18F\]F-AraG PET/CT scan and another \[18F\]F-AraG PET/CT scan 6 to 12 weeks after anti-PD-1 dose.
Patients receive oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 3 months for 2 years and then annually thereafter.
ADC-1013 (agonistic human monoclonal IgG1 anti-CD40 antibody) administered by intratumoral injection every second week for 8 weeks. Patients that do not progress will be offered continued treatment until complete response, confirmed progressive disease, or clinical deterioration.
The global elderly population, aged 65 and over, reached approximately 10% in 2020, and this proportion is expected to continue rising. Therefore, the prevalence of neurodegenerative diseases such as Parkinson's disease (PD), which are characterized by declining memory capabilities, is anticipated to increase. In a previous study, we successfully restored the diminished memory capabilities in a fruit fly model of PD by administering an omija extract. To identify functional ingredients that can enhance memory akin to the effects of the omija extract, we conducted screenings by administering halophyte extracts to the PD model. Halophytes are plants that thrive in high-salt environments, and given Korea's geographic proximity to the sea on three sides, it serves as an optimal hub for the utilization of these plants. Upon examining the effects of the oral administration of 12 halophyte extracts, Salicornia herbacea and Calystegia soldanella emerged as potential candidates for ameliorating memory loss in PD model flies. Moreover, our findings suggested that C. soldanella, but not S. herbacea, can mitigate oxidative stress in DJ-1β mutants.
The present invention relates to a condensation and purification method of cortex fraxini total coumarin. Gout has the characteristics of latent pathogenesis and difficult radical treatment; chemical medicines have the defects of large toxic or side effects to different extents; though the treatment of traditional Chinese medicines to gout obtains favorable effects, because of the complexity of the traditional Chinese medicines and compound formulas, effective components are difficult to determine, and accordingly, clinical treating effects are difficult to accurately evaluate. Simultaneously, since the component contents of the traditional Chinese medicines are different because of the difference of producing areas and batch orders, the quality of the Chinese patent medicine is caused to difficult to control. Referring to the defects of compound Chinese patent medicines, a new purpose of extract of cortex fraxini used as a single traditional Chinese medicine-cortex fraxini total coumarin is provided; a new purpose of aesculin is also provided; the single traditional Chinese medicine cortex fraxini-cortex fraxini total coumarin and the aesculin can have obvious action on delivering pain, resisting inflammation and reducing the blood uric acid of patients, and the present invention has obvious treating action on acute and chronic gout. The total effective rate is 90%; the excellence rate 56.7%, and obvious toxic or side action is not generated. The present invention has the advantages of clear effective component, outstanding treating effect and small toxic or side effect. The present invention also provides a convenient preparation method of cortex fraxini total coumarin, particularly a condensation and purification method of cortex fraxini total coumarin.
COVID-19 can present as neurological symptoms such as anosmia, headache, taste perversion, dizziness, syncope, and altered state of consciousness. It has been reported in previous studies that thromboembolic ischemic and hemorrhagic strokes associated with COVID-19 have been observed in the early period. It has been suggested that conditions characterized by neurological sequelae, such as encephalitis and encephalopathy, ataxic seizures, Guillain-Barré syndrome (GBS), demyelinating diseases, and neuromuscular disorders may occur in the longer term.In the present study, the investigators aimed to reveal the findings of neuroimaging analyses performed in patients followed up with a diagnosis of COVID-19 who had neurological symptoms, discuss the relationship of these findings with laboratory and epidemiological data, and emphasize that CNS involvement in these patients should not be overlooked. In this study, 436 patients with COVID-19 who underwent at least one neuroimaging procedure during April 2020-December 2020 due to neurological symptoms and whose diagnosis was confirmed by reverse transcriptase-polymerase chain reaction test were included. Although computed tomography was predominantly used for imaging, magnetic resonance imaging was also used when necessary. The patients were grouped based on imaging findings, and statistical evaluations were made between the groups.
INTRODUCTION: Sessile plants engage in trade-offs between growth and defense capacity in response to fluctuating environmental cues. MYB is an important transcription factor that plays many important roles in controlling plant growth and defense. However, the mechanism behind how it keeps a balance between these two physiological processes is still largely unknown.
OBJECTIVES: Our work focuses on the dissection of the molecular mechanism by which GhMYB33 regulates plant growth and defense.
METHODS: The CRISPR/Cas9 technique was used to generate mutants for deciphering GhMYB33 functions. Yeast two-hybrid, luciferase complementary imaging, and co-immunoprecipitation assays were used to prove that proteins interact with each other. We used the electrophoretic mobility shift assay, yeast one-hybrid, and luciferase activity assays to analyze GhMYB33 acting as a promoter. A β-glucuronidase fusion reporter and 5' RNA ligase mediated amplification of cDNA ends analysis showed that ghr-miR319c directedly cleaved the GhMYB33 mRNA.
RESULTS: Overexpressing miR319c-resistant GhMYB33 (rGhMYB33) promoted plant growth, accompanied by a significant decline in resistance against Verticillium dahliae. Conversely, its knockout mutant, ghmyb33, demonstrated growth restriction and concomitant augmentation of V. dahliae resistance. GhMYB33 was found to couple with the DELLA protein GhGAI1 and bind to the specific cis-elements of GhSPL9 and GhDFR1 promoters, thereby modulating internode elongation and plant resistance in V. dahliae infection. The ghr-miR319c was discovered to target and suppress GhMYB33 expression. The overexpression of ghr-miR319c led to enhanced plant resistance and a simultaneous reduction in plant height.
CONCLUSION: Our findings demonstrate that GhMYB33 encodes a hub protein and controls the expression of GhSPL9 and GhDFR1, implicating a pivotal role for the miR319c-MYB33 module to regulate the trade-offs between plant growth and defense.
The aim of the present study is to evaluate the effects of neuromuscular electrical stimulation (NMES) combined with conventional physiotherapy (Experimental Group), compared to conventional physiotherapy only (Control Group) in critically ill ICU patients, by means of a randomized controlled clinical trial. Primary outcomes evaluated during ICU patient's hospitalization are (1) the time spent in the ICU; (2) time of mechanical ventilation; (3) time and success of weaning (up to 48 hours), (4) the isometric torque from contractions artificially generated by NMES and evaluated by dynamometry; (5) muscle morphology and quality by means of ultrasonography. Secondary outcomes include (6) the sit and stand test; (7) gait speed test; (8) autonomic control (heart rate variability); (9) peripheral polyneuropathy by means of MRC scale; (10) Inflammatory profile - inflammatory (IL-6 and TNF-α) and anti-inflammatory (IL-10) cytokines; (11) blood muscular biochemical markers (IGF1, LDH, CK); (12) predictive mortality index for patients admitted to the ICU (SAPS 3); (13) survival rate; and (14) mobility (PERME). After discharge from the ICU or as soon as the patients are able to perform force voluntarily, the maximum voluntary torque will also be evaluated by means of dynamometry. Also, clinical data, hemodynamic variables, dosage of neuromuscular blockers and corticosteroids, blood glucose levels in the morning, daily water balance, oxygenation index, arterial blood gases, mechanical ventilator parameters, Glasgow scale, sedation scale (RASS), will be recorded daily. The investigators expect that the NMES program will be able to reduce muscle structure and function losses compared to control group, and will improve muscle quality, will reduce the ventilation time and the total time spent at the ICU, as well as improve functionality of these patients. In addition, the researchers expect to understand which mechanisms determine such adaptations in the musculoskeletal system of these patients.
Following intravenous injections of 12.5 mcg/kg to 125 mcg/kg to congestive heart failure patients, milrinone had a volume of distribution of 0.38 liters/kg, a mean terminal elimination half-life of 2.3 hours, and a clearance of 0.13 liters/kg/hr. Following intravenous infusions of 0.2 mcg/kg/min to 0.7 mcg/kg/min to congestive heart failure patients, the drug had a volume of distribution of about 0.45 liters/kg, a mean terminal elimination half-life of 2.4 hours, and a clearance of 0.14 liters/‌kg/‌hr. These pharmacokinetic parameters were not dose-dependent, and the area under the plasma concentration versus time curve following injections was significantly dose-dependent.

Milrinone has been shown (by equilibrium dialysis) to be approximately 70% bound to human plasma protein.

The primary route of excretion of milrinone in man is via the urine. The major urinary excretions of orally administered milrinone in man are milrinone (83%) and its 0-glucuronide metabolite (12%). Elimination in normal subjects via the urine is rapid, with approximately 60% recovered within the first two hours following dosing and approximately 90% recovered within the first eight hours following dosing. The mean renal clearance of milrinone is approximately 0.3 liters/min, indicative of active secretion.
BACKGROUND: Management of status epilepticus (SE) is focused on the early seizure termination. Refractory SE is an indication for sedation in patients with SE, but up to 75% of patients may be ventilated due to a neurological or respiratory failure. In patients requiring sedation, the clinical assessment is not sufficient to assess seizure control. Identifying those at risk of recurrent seizures could be useful to adapt their management. On the other hand, patients with low risk could benefit from an early withdrawal of sedation to avoid the impact of inappropriate sedation on outcome.
OBJECTIVE: To determine the prevalence and the predictors of uncontrolled SE and its impact on outcome in patients with generalized convulsive SE (GCSE) requiring mechanical ventilation (MV).
METHODS: We retrospectively included patients admitted to the intensive care unit with GCSE requiring MV. Uncontrolled SE was defined as persistent or recurrent seizures during sedation or within 24hours following withdrawal. A multivariable logistic regression model was used to assess the associated factors.
RESULTS: Uncontrolled SE occurred in 37 out of 220 patients (17%). Persistent seizures at admission, higher SAPS II and central nervous system infection were associated with a higher risk of uncontrolled SE. Acute toxic or metabolic etiologies were associated with a decreased risk of uncontrolled SE. In a supplementary analysis, decrease of albumin blood levels was associated with uncontrolled SE. Uncontrolled SE was associated with a poor functional outcome and mortality at 90 days.
CONCLUSIONS: Seventeen percent of patients with a GCSE requiring MV suffered from uncontrolled SE. Etiology and persistent seizures at admission were the main predictors of uncontrolled SE. Patients with uncontrolled SE had a longer duration of sedation and MV, a poor functional outcome and a higher mortality. Further studies are required to determine the impact of continuous electroencephalogram monitoring on the clinical course.
The dose of SHEN211 tablets 330mg was intended to be selected in this experiment. Subjects in group A took SHEN211 tablets 330mg orally on an empty stomach in the morning of the first day of the experiment (the first cycle). On the morning of the 12th day of the trial (the second cycle), SHEN211 tablets 330mg were taken orally once, 30min after starting to eat a high-fat high-calorie meal; Subjects in group B took SHEN211 tablets 330mg orally once in the morning of the first day of the trial (the first cycle) when they started to eat A high-fat and high-calorie meal for 30min, and took SHEN211 tablets 330mg orally in the morning of the 12th day of the trial (the second cycle) on an empty stomach.
Fluoroscopy guided periradicular lumbar infiltration. Prone position. Anatomical identification by radioscopy: antero-posterior and sagittal planes. Needle placement in an anteroposterior view, needle is then advanced in an inclined plane of 20° with respect to the initial axis, "tunnel vision" type image. Foramen is then reached in a sagittal view (not to progress too far in the intra-foraminal level). Needle progression is secured by neurostimulation (territory concerned by the root, intensity 0.2 milliampere to be at a distance of 1mm from the nerve root). Once needle is in place, fluoroscopy is performed to verify correct positioning (Omnipaque 300mg/ml of Iohexol, 0.2 to 0.5ml). Once position confirmed, mixture Depomedrol 40mg + lidocaine 2% (1ml) is injected.
The invention provides povidone-iodine powder with effective sterilization and disinfection effects. The powder comprises the following components in parts by weight: 160-260 parts of povidone-iodine, 5-10 parts of potassium iodide, 10-20 parts of potassium iodate and 10-50 parts of glycerinum. The invention also provides a method for preparing the povidone-iodine powder. The method comprises the following steps: 1, dispersing povidone-iodine, potassium iodide and potassium iodate in a solvent; 2, dispersing glycerinum in the mixture obtained in the step 1; 3, removing the solvent to obtain the powder. The povidone-iodine powder belongs to an effective, broad-spectrum, safe and quick disinfection preservative, plays a good role in killing various bacteria, spores, viruses, fungi and the like, and acts by depolymerizing to release iodine after being contacted with a wound or an infected part so as to play the effect of sterilizing. The povidone-iodine powder has small irritation to tissues, is suitable for disinfecting skin and mucosal infections, and is stable in storage and convenient to transport and use.
PURPOSE:A purified blood derived from pig blood, obtained by treating a blood plasma separated from a pig blood with an ultrafiltration membrane for a given molecular weight range, and removing a salt, low-molecular weight protein, etc., capable of exhibiting an antimicrobial activity and an antibody value against pathogenic coliform bacilli, effective for preventing diseases caused by coliform bacilli of newborn animals. CONSTITUTION:A fresh blood collected from a pig body by the direct blood collecting method while avoiding the contact with air is rapidly cooled to a temperature at which the multiplication of microorganisms will not occur, e.g. about 4-5 deg.C. The resultant cooled blood is then centrifuged at <=5,000r.p.m. rotational frequency to give a supernatant fraction, which is then ultrafiltered through a filtration membrane for 6,000-13,000 fractionated molecular weight while being kept at a low temperature to purify the blood plasma component. Preferably, the removal ratio of foreign materials in the purification treatment is about 70-90%. The resultant purified concentrated liquid is then dried into powder by the freeze-dryig method, etc. and give the aimed purified blood plasma containing albumin and total globulin in (40-50):(50-60) ratio between the albumin and the total globulin in the whole protein. An antibiotic substance ''Colistin '' is added to the purified blood plasma and used together to give an artificial milk for animals.
<P>PROBLEM TO BE SOLVED: To obtain an external preparation for skins which shows an excellent stability and safety, is highly effective in moisturizing skins, producing beautiful skins and alleviating rough skin problems and fits comfortably to skins, by sufficiently improving physiological functions of the skins.  <P>SOLUTION: The external preparation for skins is allowed to contain an extract mixture comprising extracts from Matricaria chamomilla L., Foeniculum vulgare Miller, Humulus lupulus L., Achillea millefolium L., Melissa officinalis L. and Viscum coloratum Nakai var. lutescens Miyabe et Kudo or Viscum album L. var. lutescens Makino, extracts from Foeniculum vulgare Miller, Aesculus turbinata Blume and/or Aesculus hippocastanum L. and Daucus carota L., extracts from Matricaria chamomilla L., Achillea millefolium L., at least one Hypericum spp., Tussilago farfara L., Althaea officinalis L. and Salvia officinalis L. and/or its variant, or extracts from Salvia officinalis L. and/or its variant, Hamamelis virginiana L., Thymus vulgaris L., Potentilla tormentilla and Rosmarinus officinalis L., in combination with at least one extract chosen from a group consisting of extracts of specific plant species. At least two preparations chosen from these are used for treating skins.  <P>COPYRIGHT: (C)2004,JPO
Subjects receive Sham sessions (no electric current) once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday). After a washout period of 16 weeks, subjects receive High Dose transcranial Direct Current Stimulation (HD-tDCS) lasting 20 minutes at an electric current intensity of up to 2mA in the left posterior temporo-parietal cortex (TPC). Stimulation sessions are delivered once a day (QD) for a total of 10 sessions over 2 weeks (Monday-Friday).